HomeCompareTCON vs PLD

TCON vs PLD: Dividend Comparison 2026

TCON yields 6211.18% · PLD yields 3.18%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TCON wins by $514736922231171.44M in total portfolio value
10 years
TCON
TCON
● Live price
6211.18%
Share price
$0.03
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$514736922231177.94M
Annual income
$498,935,081,000,370,800,000.00
Full TCON calculator →
PLD
PLD
● Live price
3.18%
Share price
$128.78
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$6.50M
Annual income
$5,256,436.18
Full PLD calculator →

Portfolio growth — TCON vs PLD

📍 TCON pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTCONPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TCON + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TCON pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TCON
Annual income on $10K today (after 15% tax)
$527,950.31/yr
After 10yr DRIP, annual income (after tax)
$424,094,818,850,315,200,000.00/yr
PLD
Annual income on $10K today (after 15% tax)
$270.62/yr
After 10yr DRIP, annual income (after tax)
$4,467,970.75/yr
At 15% tax rate, TCON beats the other by $424,094,818,850,310,700,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TCON + PLD for your $10,000?

TCON: 50%PLD: 50%
100% PLD50/50100% TCON
Portfolio after 10yr
$257368461115592.22M
Annual income
$249,467,540,500,188,040,000.00/yr
Blended yield
96.93%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

TCON
Analyst Ratings
14
Buy
2
Hold
Consensus: Buy
Altman Z
-44.2
Piotroski
6/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+5.6% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TCON buys
0
PLD buys
0
No recent congressional trades found for TCON or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTCONPLD
Forward yield6211.18%3.18%
Annual dividend / share$2.00$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4%
Portfolio after 10y$514736922231177.94M$6.50M
Annual income after 10y$498,935,081,000,370,800,000.00$5,256,436.18
Total dividends collected$513674666624982.00M$6.37M
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy

Year-by-year: TCON vs PLD ($10,000, DRIP)

YearTCON PortfolioTCON Income/yrPLD PortfolioPLD Income/yrGap
1← crossover$631,818$621,118.01$11,255$555.24+$620.6KTCON
2$37,352,078$36,676,032.53$13,062$1,018.59+$37.34MTCON
3$2,066,348,794$2,026,382,070.58$15,903$1,926.67+$2066.33MTCON
4$106,978,454,906$104,767,461,696.78$20,839$3,823.32+$106978.43MTCON
5$5,183,619,185,269$5,069,152,238,519.27$30,464$8,166.08+$5183619.15MTCON
6$235,102,301,025,325$229,555,828,497,087.03$52,054$19,457.30+$235102300.97MTCON
7$9,981,906,672,630,884$9,730,347,210,533,788.00$109,886$54,188.93+$9981906672.52MTCON
8$396,781,870,195,426,800$386,101,230,055,711,700.00$304,030$186,451.18+$396781870195.12MTCON
9$14,768,075,916,642,124,000$14,343,519,315,533,017,000.00$1,166,125$840,813.32+$14768075916640.96MTCON
10$514,736,922,231,177,940,000$498,935,081,000,370,800,000.00$6,504,190$5,256,436.18+$514736922231171.44MTCON

TCON vs PLD: Complete Analysis 2026

TCONStock

TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of soft tissue sarcoma; and YH001, an investigational humanized CTLA-4 IgG1 monoclonal antibody for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors and lymphomas, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309; Case Western Reserve University for the development of TRC102; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.

Full TCON Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this TCON vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TCON vs SCHDTCON vs JEPITCON vs OTCON vs KOTCON vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.